注射美国安进狄诺塞麦需要注意什么事项？

(Denosumab) is a human RANKL monoclonal antibody (IgG2) with high affinity and specificity. It acts on and binds to RANKL, preventing its binding to RANK on the surface of osteoclast precursor cells and mature cells, thereby inhibiting osteoclast differentiation, activation and survival. In order for patients to continue to benefit from it, what should be paid attention to when injecting Amgen denosumab?

1. When receiving denosumab treatment, you should avoid using other drugs with similar active ingredients to this product [such as Xgeva and Prolia are both denosumab preparations (trade names of this product produced by Amgen)].

2. If the patient misses denosumab, it should be replenished as soon as possible and used again six months after the replenishment.

3. Patients with hypocalcemia should correct hypocalcemia before receiving denosumab treatment; patients who are prone to induce hypocalcemia (patients with severe renal insufficiency and undergoing dialysis treatment) and mineral disorders in the body should conduct clinical monitoring of blood calcium and mineral (phosphorus and magnesium) levels in the body while receiving this product, and take appropriate amounts of calcium tablets and vitamin D.

4. The use of denosumab can cause serious infections such as skin infections, abdominal infections, urinary tract infections and ear infections. Patients receiving this product should seek medical observation immediately if they find signs or symptoms of serious infections. Combining it with immunosuppressants or drugs that damage the immune system can increase the risk of serious infections. Patients who have serious infections need to weigh the pros and cons of using this product.

Amgen focuses on disease areas with huge medical needs that are far from being met, and uses its advanced experience in biopharmaceuticals to make outstanding contributions to improving human health and quality of life. Since its founding in 1980, Amgen has become one of the world's leading independent biotechnology companies, providing innovative drugs to millions of patients in more than 100 countries and regions around the world. It also has a number of promising drugs under development, including bone metastasis drugs.

Recommended hot articles: /newsDetail/87484.html